Show simple item record

dc.contributor.authorBonovas, Stefanosen
dc.contributor.authorNikolopoulos, Georgios K.en
dc.contributor.authorPiovani, Danieleen
dc.contributor.authorGonzález‐Lorenzo, Marienen
dc.contributor.authorPantavou, Katerinaen
dc.contributor.authorLytras, Theodoreen
dc.contributor.authorPeyrin‐Biroulet, Laurenten
dc.contributor.authorDanese, Silvioen
dc.creatorBonovas, Stefanosen
dc.creatorNikolopoulos, Georgios K.en
dc.creatorPiovani, Danieleen
dc.creatorGonzález‐Lorenzo, Marienen
dc.creatorPantavou, Katerinaen
dc.creatorLytras, Theodoreen
dc.creatorPeyrin‐Biroulet, Laurenten
dc.creatorDanese, Silvioen
dc.description.abstractAims The comparative efficacy, safety and tolerability of budesonide-MMX and oral mesalamine in active, mild-to-moderate ulcerative colitis (UC) are unclear. We conducted a network meta-analysis to fill this evidence gap. Methods We searched PubMed, Scopus, Embase, the Cochrane Library, clinical trial registries, regulatory agencies' websites and international conference proceedings, up to July 2018, to identify randomized controlled trials of adult patients with active, mild-to-moderate UC, comparing budesonide-MMX or mesalamine against placebo, or against each other, or different dosing strategies, for induction of remission. Two reviewers independently abstracted study data and outcomes, and assessed each trial's risk-of-bias. Results We identified and synthesized evidence from 15 eligible trials including 4083 participants. Budesonide-MMX 9 mg/day and mesalamine >2.4 g/day had similar efficacy for induction of clinical and endoscopic remission (OR = 0.97en
dc.description.abstract0.59–1.60), both showing superiority over placebo (OR = 2.68en
dc.description.abstract1.75–4.10, and OR = 2.75en
dc.description.abstract1.94–3.90, respectively). Furthermore, mesalamine >2.4 g/day was more efficacious than mesalamine 1.6–2.4 g/day (odds ratio = 1.27en
dc.description.abstract1.03–1.56). Secondary analyses showed that mesalamine >2.4 g/day ranks at the top among comparator treatments regarding safety (serious adverse eventsen
dc.description.abstractsurface under the cumulative ranking area [SUCRA] 79.2%) and tolerability (treatment discontinuations or withdrawals from the study due to adverse eventsen
dc.description.abstractSUCRA 96.7%). There was no evidence of inconsistency, while heterogeneity between studies and risk of publication bias were low. Conclusion Budesonide-MMX and mesalamine >2.4 g/day had similar efficacy for induction of clinical and endoscopic remission in active, mild-to-moderate UCen
dc.description.abstracthowever, mesalamine >2.4 g/day showed better tolerability. Further high-quality research is warranted.en
dc.sourceBritish Journal of Clinical Pharmacologyen
dc.titleComparative assessment of budesonide-MMX and mesalamine in active, mild-to-moderate ulcerative colitis: A systematic review and network meta-analysisen
dc.description.endingpage2254Ιατρική Σχολή / Medical SchoolΙατρική Σχολή / Medical School
dc.contributor.orcidNikolopoulos, Georgios K. [0000-0002-3307-0246]
dc.contributor.orcidBonovas, Stefanos [0000-0001-6102-6579]
dc.contributor.orcidPantavou, Katerina [0000-0002-9176-4369]
dc.contributor.orcidPiovani, Daniele [0000-0002-1414-6639]
dc.contributor.orcidDanese, Silvio [0000-0001-7341-1351]
dc.contributor.orcidLytras, Theodore [0000-0002-4146-4122]

Files in this item


There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record